Variant · Other
KMT2A Mutation
CI-VAR-00002822Explore in graph →CIViC 4936
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33653367
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| KMT2C Mutation OR KMT2D mutation OR KMT2A Mutation OR KMT2B Mutation | Immune Checkpoint Inhibitor | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID12593In a retrospective pan-cancer analysis of four immune checkpoint therapy (ICT)–treated cohorts (melanoma n = 287; NSCLC n = 131; total n = 418), KMT2 family mutations were associated with improved ICT… (full text at CIViC) PMID 33653367 · Zhang et al., 2021 · Open in CIViC | civic |
| Malignant Neoplasm1 | ||||||||
| KMT2C Mutation OR KMT2A Mutation | Immunotherapy | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12031This study examined the role of KMT2A/C mutations as a potential biomarker for predicting the effectiveness of immunotherapy. In the primary ICI-treated cohort (n = 546), the researchers observed that… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available